Limits...
Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer.

Ma JT, Zheng JH, Han CB, Guo QY - Cancer Sci. (2014)

Bottom Line: The combined odds ratios (ORs) indicated no significant difference in palliation of cough, chest pain, and hemoptysis between the higher dose and lower dose RT groups (combined ORs = 0.88, 1.83, 1.39, respectively).The 1- and 2-year OS rates were similar between the high and low dose RT groups (combined ORs = 1.09 and 1.38, respectively).This meta-analysis indicates that high dose (≥30 Gy) and lower dose (<30 Gy) RT provide similar symptom palliation and 1- and 2-year OS in patients with locally advanced lung cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Show MeSH

Related in: MedlinePlus

Forest plots of the meta-analysis comparing higher dose (≥30 Gy) versus lower dose (<30 Gy) radiotherapy for palliation of symptoms. (a) Cough; (b) chest pain; (c) hemoptysis. CI, confidence interval; RT, radiotherapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317848&req=5

fig02: Forest plots of the meta-analysis comparing higher dose (≥30 Gy) versus lower dose (<30 Gy) radiotherapy for palliation of symptoms. (a) Cough; (b) chest pain; (c) hemoptysis. CI, confidence interval; RT, radiotherapy.

Mentions: One study(13) did not report relevant data with respect to the primary outcome of palliation of cough; thus, four studies were included in the analysis of palliation of cough. After pooling of data, no significant heterogeneity among the studies was found (Q = 4.30, df = 3, P = 0.230; I2 = 30.30%); therefore, a fixed-effects model was used for the analysis. The combined OR revealed no significant difference in palliation of cough between patients treated with a higher RT dose compared to those treated with a lower RT dose. Among the four studies, ORs ranged from 0.69 to 1.33, with the combined OR = 0.88 (95% CI = 0.71–1.08, P = 0.217, Fig. 2a).


Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer.

Ma JT, Zheng JH, Han CB, Guo QY - Cancer Sci. (2014)

Forest plots of the meta-analysis comparing higher dose (≥30 Gy) versus lower dose (<30 Gy) radiotherapy for palliation of symptoms. (a) Cough; (b) chest pain; (c) hemoptysis. CI, confidence interval; RT, radiotherapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317848&req=5

fig02: Forest plots of the meta-analysis comparing higher dose (≥30 Gy) versus lower dose (<30 Gy) radiotherapy for palliation of symptoms. (a) Cough; (b) chest pain; (c) hemoptysis. CI, confidence interval; RT, radiotherapy.
Mentions: One study(13) did not report relevant data with respect to the primary outcome of palliation of cough; thus, four studies were included in the analysis of palliation of cough. After pooling of data, no significant heterogeneity among the studies was found (Q = 4.30, df = 3, P = 0.230; I2 = 30.30%); therefore, a fixed-effects model was used for the analysis. The combined OR revealed no significant difference in palliation of cough between patients treated with a higher RT dose compared to those treated with a lower RT dose. Among the four studies, ORs ranged from 0.69 to 1.33, with the combined OR = 0.88 (95% CI = 0.71–1.08, P = 0.217, Fig. 2a).

Bottom Line: The combined odds ratios (ORs) indicated no significant difference in palliation of cough, chest pain, and hemoptysis between the higher dose and lower dose RT groups (combined ORs = 0.88, 1.83, 1.39, respectively).The 1- and 2-year OS rates were similar between the high and low dose RT groups (combined ORs = 1.09 and 1.38, respectively).This meta-analysis indicates that high dose (≥30 Gy) and lower dose (<30 Gy) RT provide similar symptom palliation and 1- and 2-year OS in patients with locally advanced lung cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Show MeSH
Related in: MedlinePlus